NPC Partners with NCCN to Expand
Breast Cancer Database
Data on Use of New Pharmaceuticals in
Community Cancer Centers
to be Included
RESTON, VA (December 27, 2000) — A research collaboration
between the National Pharmaceutical Council (NPC) and the National
Comprehensive Cancer Network (NCCN) will expand the NCCN Breast
Cancer Outcomes Database to facilitate the participation of community-based
cancer centers in this national database. Tracking the pattern of
use of pharmaceuticals and the feedback of such information to facilitate
the appropriate use of chemotherapies, especially new, promising
agents, is among the primary objectives of the NCCN Database.
The collaborative effort will analyze of the introduction and diffusion
of new pharmaceuticals in the NCCN centers and in affiliate community
centers. The data gathered will be used to better understand how
pharmaceuticals are being used and will provide information regarding
utilization patterns of pharmaceuticals by thought leaders at the
NCCN centers to participating community centers and to the oncology
community at large.
"We are very excited about this opportunity to expand on the
research into appropriate cancer care that both NPC and NCCN are
actively engaged in and to educate those in the field about state-of-the-art
treatments," said Dr. Jeann Lee Gillespie, director of scientific
affairs for NPC.
The data will be gathered from major academic medical centers and
community cancer centers around the country. Academic medical centers
participating in the NCCN Database include: Dana-Farber Cancer Institute,
Roswell Park Cancer Institute, Fox Chase Cancer Center, City of
Hope National Medical Center, H. Lee Moffitt Cancer Center, Arthur
G. James Cancer Hospital and Richard J. Solove Research Institute
at Ohio State University, Memorial Sloan-Kettering Cancer Center,
Stanford Hospital and Clinics, University of Michigan Comprehensive
Cancer Center, the UNMC/Eppley Cancer Center at the University of
Nebraska Medical Center, the University of Texas M. D. Anderson
Cancer Center. The community cancer centers involved will be selected
in the near future.
"The NCCN is very pleased to join the NPC in a major national
effort to advance the state-of-the-art in cancer care," said
Dr. William McGivney, NCCN's Chief Executive Officer. "The
NCCN Oncology Outcomes Database is the most comprehensive of all
existing databases on breast cancer patients. Chemotherapy plays
a critical role in improving the outcomes for cancer patients. By
advancing the data and information available on the application
of important new therapies, we will work to improve the quality
of care available to the patients whom we serve."
The NCCN is an alliance of 18 of the world's leading cancer centers,
established in 1995 to provide the state-of-the-art in cancer care
to the greatest number of patients in need. The NCCN member institutions
are: The Arthur G. James Cancer Hospital & Solove Research Institute
at Ohio State University, Columbus; City of Hope National Medical
Center, Los Angeles; Dana-Farber Cancer Institute, Boston; Fox Chase
Cancer Center, Philadelphia; Fred Hutchinson Cancer Research Center,
Seattle; H. Lee Moffitt Cancer Center & Research Institute at
the University of South Florida, Tampa; Huntsman Cancer Institute
at the University of Utah, Salt Lake City; Johns Hopkins Oncology
Center, Baltimore; Memorial Sloan-Kettering Cancer Center, New York;
Robert H. Lurie Comprehensive Cancer Center of Northwestern University,
Chicago; Roswell Park Cancer Institute, Buffalo; St. Jude Children's
Research Hospital, Memphis; Stanford Health Care, Stanford; University
of Alabama at Birmingham Comprehensive Cancer Center, Birmingham;
UCSF Comprehensive Cancer Center, San Francisco; University of Michigan
Comprehensive Cancer Center, Ann Arbor; UNMC/Eppley Cancer Center
at the University of Nebraska Medical Center, Omaha; and University
of Texas M. D. Anderson Cancer Center, Houston. For more information
about NCCN, please visit www.nccn.org.
Since 1953, NPC has sponsored and conducted scientific, evidence-based
analyses of the appropriate use of pharmaceuticals and the clinical
and economic value of pharmaceutical innovation. NPC provides educational
resources to a variety of health care stakeholders, including patients,
clinicians, payers and policy makers. More than 20 research-based
pharmaceutical companies are members of the NPC.
###
Please direct all media inquiries to Pat Adams, phone
(703) 620-6390.
|
